Topics: Diseases

  • 16 countries. 32,000 respondents. Hybrid press conference on 19 September 2023, from 11 am (CEST)

    STADA Health Report 2023: Invitation to the international hybrid STADA press conference

    Dear Editorial Team
    The fifth international STADA Health Report focuses on how Europeans are caring for their own health in times of crisis – by taking preventive and not merely reactive measures.
    The first results of the representative online study conducted by the market research institute Human8 Consulting on behalf of STADA Arzneimittel AG will be presented to you at our international hy

  • STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty

    Double-digit growth journey continues with 16% sales increase to €2.1bn1 and 30% EBITDA to €509 million[1] in first six months of 2023 Organic growth in Consumer Healthcare is largest contributor to record performance; Specialty segment with double-digit growth as well. Market-share gains in Generics STADA CEO Peter Goldschmidt: “STADA’s purpose, values and strategy are the base for our continue

Enter your email address to follow STADA Arzneimittel AG

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow STADA Arzneimittel AG.

Okay